Tomoo Fujisawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomoo Fujisawa has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Haruki Komatsu
Department of Pediatrics, Toho University, Sakura Medical Center, Chiba, Japan
21 shared publications - Ayano Inui
Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohamashi Tobu Hospital, Yokohama 230-0012, Japan
17 shared publications - Tsuyoshi Sogo
Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama City Tobu Hospital, Yokohama, Kanagawa, Japan
16 shared publications - Ayano Inui
Saiseikai Yokohamashi Tobu Hospital
5 shared publications - Tomoyuki Tsunoda
Division of Hepatology and Gastroenterology, Children's Center for Health and Development, Saiseikai Yokohamashi Tobu Hospital, Sakura, Chiba, Japan
5 shared publications - Eitaro Hiejima
Department of Pediatrics, Yokohama Eastern Hospital, 3-6-1 Shimosueyoshi Tsurumi Yokohama, Kanagawa 230-0012, Japan
3 shared publications
Latest Publications
- 1 December 2015
- p. 685-91
[IFN therapy in children with chronic hepatitis B].
- Open Access
- 20 August 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 1-10
Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice
- 20 August 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 1-10
Open AccessLack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice
- 22 January 2015
- Published by Wiley in Pediatrics International
- Vol. 57 (3) , 401-405
Hepatitis B (HB) immunoglobulin plus HB vaccine for intrauterine HB virus infection
Vaccination against hepatitis B virus (HBV) infection in infants born to hepatitis B surface antigen (HBsAg)-positive mothers using HB immunoglobulin (HBIG) and hepatitis B (HB) vaccine was launched in Japan in 1985. Infants testing positive for HBsAg at 1 month of age are considered to have prenatally acquired the infection and are usually excluded from the prevention program. Infants born to HB e antigen (HBeAg)-positive mothers are at a high risk of perinatally acquiring the infection. In this study, long-term outcome was evaluated in children with prenatal HBV infection who received the HBIG and HB vaccine in Japan.Newborns of both HBsAg- and HBeAg-positive carrier mothers received HBIG within 48 h of birth and at 2 months of age. Subsequently, three doses of recombinant HB vaccine were given at 2, 3, and 5 months of age. Outcome was compared between the following two groups: infants who completed the vaccination program, even if they were HBsAg positive at 1 month of age (n = 15), and infants who did not (n = 51).Seroconversion from HBeAg to anti-HBe antibody (HBeAb) before 3 years of age was observed in five children (33%) who completed the vaccination program and in two (4%) who did not (P = 0.005). In 2/5 children who completed the vaccination program and achieved HBeAb seroconversion, seroconversion from HBsAg to anti-HBs antibody was also noted.This specific vaccination program for children with prenatal HBV infection has the potential to alter immune tolerance to HBV.
- 22 January 2015
- Published by Wiley in Pediatrics International
- Vol. 57 (3) , 401-405
Hepatitis B (HB) immunoglobulin plus HB vaccine for intrauterine HB virus infection
Vaccination against hepatitis B virus (HBV) infection in infants born to hepatitis B surface antigen (HBsAg)-positive mothers using HB immunoglobulin (HBIG) and hepatitis B (HB) vaccine was launched in Japan in 1985. Infants testing positive for HBsAg at 1 month of age are considered to have prenatally acquired the infection and are usually excluded from the prevention program. Infants born to HB e antigen (HBeAg)-positive mothers are at a high risk of perinatally acquiring the infection. In this study, long-term outcome was evaluated in children with prenatal HBV infection who received the HBIG and HB vaccine in Japan.Newborns of both HBsAg- and HBeAg-positive carrier mothers received HBIG within 48 h of birth and at 2 months of age. Subsequently, three doses of recombinant HB vaccine were given at 2, 3, and 5 months of age. Outcome was compared between the following two groups: infants who completed the vaccination program, even if they were HBsAg positive at 1 month of age (n = 15), and infants who did not (n = 51).Seroconversion from HBeAg to anti-HBe antibody (HBeAb) before 3 years of age was observed in five children (33%) who completed the vaccination program and in two (4%) who did not (P = 0.005). In 2/5 children who completed the vaccination program and achieved HBeAb seroconversion, seroconversion from HBsAg to anti-HBs antibody was also noted.This specific vaccination program for children with prenatal HBV infection has the potential to alter immune tolerance to HBV.
- 1 January 2015
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 60 (1) , 99-104
Chronic Hepatitis B Virus Infection in Children and Adolescents in Japan
Background: Hepatitis B e antigen (HBeAg) seroconversion is an important event in patients with chronic hepatitis B virus (HBV) infection. This study aimed to clarify the outcome of long-term follow-up of chronic HBV infection and the factors affecting HBeAg seroconversion in children in Japan. Methods: Patients who were first examined at our institution between 1980 and 2012, who were P < 0.05). Kaplan-Meier analysis showed that the median times to HBeAg seroconversion (50% achievement of HBeAg seroconversion) of the treated and untreated children were 10.2 and 12.0 years, respectively. The cumulative proportion of HBeAg seroconversion was significantly higher in the treated children than in the untreated children (P = 0.02). Conclusions: A higher serum ALT level was a predictor for HBeAg seroconversion. Antiviral treatment could accelerate the achievement of HBeAg seroconversion in HBV-infected children.
- 1 January 2015
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 60 (1) , 99-104
Chronic Hepatitis B Virus Infection in Children and Adolescents in Japan
Background: Hepatitis B e antigen (HBeAg) seroconversion is an important event in patients with chronic hepatitis B virus (HBV) infection. This study aimed to clarify the outcome of long-term follow-up of chronic HBV infection and the factors affecting HBeAg seroconversion in children in Japan. Methods: Patients who were first examined at our institution between 1980 and 2012, who were P < 0.05). Kaplan-Meier analysis showed that the median times to HBeAg seroconversion (50% achievement of HBeAg seroconversion) of the treated and untreated children were 10.2 and 12.0 years, respectively. The cumulative proportion of HBeAg seroconversion was significantly higher in the treated children than in the untreated children (P = 0.02). Conclusions: A higher serum ALT level was a predictor for HBeAg seroconversion. Antiviral treatment could accelerate the achievement of HBeAg seroconversion in HBV-infected children.
- Open Access
- 6 November 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 789
Association between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children
The disease progression following hepatitis B virus (HBV) infection is associated with single-nucleotide polymorphisms (SNPs). However, the role of SNPs in chronic HBV infection in children remains unclear. Here, we investigate the association between SNPs and early spontaneous hepatitis B e antigen (HBeAg) seroconversion in children with chronic hepatitis B infection. This was a retrospective cohort study. We genotyped seven SNPs in the following genes, interleukin (IL)-10 (rs1800871 and rs1800872), human leukocyte antigen (HLA)-DPA1 (rs3077), HLA-DPB1 (rs9277535), HLA-DQB2 (rs7453920), HLA-DQB1 (rs2856718), and IL28B (rs8099917), in patients with chronic HBV infection using PCR and sequencing. These variants were analyzed for an association with early HBeAg seroconversion in children. Of 225 Japanese patients with chronic hepatitis B virus infection (male/female: 105/120, median age at initial visit: 6 years; range 0–44 years), 52 achieved spontaneous HBeAg seroconversion at the age of 10 years or younger (G1: early seroconversion group), and 57 did not achieve spontaneous HBeAg seroconversion under the age of 20 years (G2: late or no seroconversion group). Of the seven SNPs, only the HLA-DPA1 SNP displayed a low p-value (P = 0.070), but not significant, to have early HBeAg seroconversion in the dominant model and in the allele model (P = 0.073) using the chi-square test. The association study found a low p-value, but not significant, to have early HBeAg seroconversion in the dominant model for HLA-DPA1 (genotype TC + TT vs. CC, P = 0.070, odds ratio: 2.016, 95% confidence interval: 0.940-4.323) using a logistic regression model. Although the HLA-DPA1 SNP did not show a statistically significant association with early HBeAg seroconversion in this study, the HLA-DPA1 SNP might increase the likelihood of achieving early spontaneous HBeAg seroconversion in children.
- 6 November 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 789
Open AccessAssociation between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children
The disease progression following hepatitis B virus (HBV) infection is associated with single-nucleotide polymorphisms (SNPs). However, the role of SNPs in chronic HBV infection in children remains unclear. Here, we investigate the association between SNPs and early spontaneous hepatitis B e antigen (HBeAg) seroconversion in children with chronic hepatitis B infection. This was a retrospective cohort study. We genotyped seven SNPs in the following genes, interleukin (IL)-10 (rs1800871 and rs1800872), human leukocyte antigen (HLA)-DPA1 (rs3077), HLA-DPB1 (rs9277535), HLA-DQB2 (rs7453920), HLA-DQB1 (rs2856718), and IL28B (rs8099917), in patients with chronic HBV infection using PCR and sequencing. These variants were analyzed for an association with early HBeAg seroconversion in children. Of 225 Japanese patients with chronic hepatitis B virus infection (male/female: 105/120, median age at initial visit: 6 years; range 0–44 years), 52 achieved spontaneous HBeAg seroconversion at the age of 10 years or younger (G1: early seroconversion group), and 57 did not achieve spontaneous HBeAg seroconversion under the age of 20 years (G2: late or no seroconversion group). Of the seven SNPs, only the HLA-DPA1 SNP displayed a low p-value (P = 0.070), but not significant, to have early HBeAg seroconversion in the dominant model and in the allele model (P = 0.073) using the chi-square test. The association study found a low p-value, but not significant, to have early HBeAg seroconversion in the dominant model for HLA-DPA1 (genotype TC + TT vs. CC, P = 0.070, odds ratio: 2.016, 95% confidence interval: 0.940-4.323) using a logistic regression model. Although the HLA-DPA1 SNP did not show a statistically significant association with early HBeAg seroconversion in this study, the HLA-DPA1 SNP might increase the likelihood of achieving early spontaneous HBeAg seroconversion in children.
- 29 July 2014
- Published by Wiley in Hepatology Research
- Vol. 45 (5) , 601-605
Neonatal liver failure owing to gestational alloimmune liver disease without iron overload
Although neonatal hemochromatosis (NH) is a well-known cause of liver failure during the neonatal period and iron deposition in extrahepatic tissues is considered essential in the diagnosis of NH, there is no consensus regarding the pathology or diagnostic criteria of NH. Recent studies of immunohistochemical assays have shown that the C5b-9 complex (the terminal membrane attack complement complex) is strongly expressed in the liver of NH cases, suggesting that a gestational alloimmune mechanism is the cause of liver injury. The patient was a low birthweight primiparous male born at 37 weeks of gestation by vaginal delivery. Blood tests 3 h after birth showed signs of liver failure, including high transferrin saturation, resembling the clinical characteristics of NH. However, magnetic resonance imaging and a lip biopsy showed no obvious iron deposition outside the liver. The patient was refractory to exchange transfusion and immunoglobulin therapy but was successfully treated by liver transplantation. Histologically, the explanted liver showed established cirrhosis, with large amounts of human C5b-9 in the residual hepatocytes, suggesting the alloimmune mechanism of liver injury was the cause of his liver failure. Liver failure caused by a gestational alloimmune mechanism should be considered in patients with antenatal liver failure, even without obvious extrahepatic siderosis.
- 29 July 2014
- Published by Wiley in Hepatology Research
- Vol. 45 (5) , 601-605
Neonatal liver failure owing to gestational alloimmune liver disease without iron overload
Although neonatal hemochromatosis (NH) is a well-known cause of liver failure during the neonatal period and iron deposition in extrahepatic tissues is considered essential in the diagnosis of NH, there is no consensus regarding the pathology or diagnostic criteria of NH. Recent studies of immunohistochemical assays have shown that the C5b-9 complex (the terminal membrane attack complement complex) is strongly expressed in the liver of NH cases, suggesting that a gestational alloimmune mechanism is the cause of liver injury. The patient was a low birthweight primiparous male born at 37 weeks of gestation by vaginal delivery. Blood tests 3 h after birth showed signs of liver failure, including high transferrin saturation, resembling the clinical characteristics of NH. However, magnetic resonance imaging and a lip biopsy showed no obvious iron deposition outside the liver. The patient was refractory to exchange transfusion and immunoglobulin therapy but was successfully treated by liver transplantation. Histologically, the explanted liver showed established cirrhosis, with large amounts of human C5b-9 in the residual hepatocytes, suggesting the alloimmune mechanism of liver injury was the cause of his liver failure. Liver failure caused by a gestational alloimmune mechanism should be considered in patients with antenatal liver failure, even without obvious extrahepatic siderosis.
- 21 July 2014
- Published by Springer Nature
- p. 121-126
Pediatric Autoimmune Hepatitis
- 1 October 2012
- Vol. 70 (10) , 1827-34
[Pediatric nonalcoholic fatty liver disease/nonalcoholic steatohepatitis].
Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is a hepatic disease associated with metabolic syndrome. In recent years, pediatric NAFLD has increased in line with the increased prevalence of pediatric obesity. The estimated prevalence of pediatric NAFLD is 2.6-9.6%. With regard to the pathogenesis of NAFLD/ NASH, the "two-hit" or "multiple-hit" hypothesis is widely accepted, and many genetic and environmental factors are associated with the development of NAFLD/NASH. Liver biopsy is regarded as the gold standard for the diagnosis of NAFLD/NASH. Pediatric NAFLD has different histopathological characteristics from those of adult NAFLD. Although pharmacotherapy has been studied in clinical trials, lifestyle modification by diet and exercise remains the mainstay of treatment for NAFLD/NASH.
- 1 October 2012
- Vol. 70 (10) , 1827-34
[Pediatric nonalcoholic fatty liver disease/nonalcoholic steatohepatitis].
Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is a hepatic disease associated with metabolic syndrome. In recent years, pediatric NAFLD has increased in line with the increased prevalence of pediatric obesity. The estimated prevalence of pediatric NAFLD is 2.6-9.6%. With regard to the pathogenesis of NAFLD/ NASH, the "two-hit" or "multiple-hit" hypothesis is widely accepted, and many genetic and environmental factors are associated with the development of NAFLD/NASH. Liver biopsy is regarded as the gold standard for the diagnosis of NAFLD/NASH. Pediatric NAFLD has different histopathological characteristics from those of adult NAFLD. Although pharmacotherapy has been studied in clinical trials, lifestyle modification by diet and exercise remains the mainstay of treatment for NAFLD/NASH.
- 1 August 2012
- Vol. 70 (8) , 1357-61
[Clostridium perfringens].
In Japan, Clostridium perfringens (C. perfringens) is the top 5th or 6th pathogen of foodborne illnesses. Annually between 2006 and 2010, there were between 20 and 40 reported outbreaks of foodborne illnesses caused by C. perfringens. C. perfringens is found in soil and dust, in the intestinal tract humans and animals, on the surface of vegetable products. C. perfringens produces an enterotoxin that causes diarrhea and abdominal pain. Inappropriate food handing practice (inadequate heating, cooling and reheating) can lead to an outbreak. In general, clinical symptoms are mild and short duration. The diagnosis of C. perfringens food poisoning is based on either quantitative cultures of implicated foods or enterotoxin-positive stool specimens. Antibiotics are not indicated.
- 1 August 2012
- Vol. 70 (8) , 1357-61
[Clostridium perfringens].
In Japan, Clostridium perfringens (C. perfringens) is the top 5th or 6th pathogen of foodborne illnesses. Annually between 2006 and 2010, there were between 20 and 40 reported outbreaks of foodborne illnesses caused by C. perfringens. C. perfringens is found in soil and dust, in the intestinal tract humans and animals, on the surface of vegetable products. C. perfringens produces an enterotoxin that causes diarrhea and abdominal pain. Inappropriate food handing practice (inadequate heating, cooling and reheating) can lead to an outbreak. In general, clinical symptoms are mild and short duration. The diagnosis of C. perfringens food poisoning is based on either quantitative cultures of implicated foods or enterotoxin-positive stool specimens. Antibiotics are not indicated.
- Open Access
- 10 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 22
Hepatitis B surface gene 145 mutant as a minor population in hepatitis B virus carriers
Hepatitis B virus (HBV) can have mutations that include the a determinant, which causes breakthrough infection. In particular, a single mutation at amino acid 145 of the surface protein (G145) is frequently reported in the failure of prophylactic treatment. The aim of this study was to evaluate the frequency of the a determinant mutants, especially the G145 variant, in Japan, where universal vaccination has not been adopted.
- 10 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 22
Open AccessHepatitis B surface gene 145 mutant as a minor population in hepatitis B virus carriers
Hepatitis B virus (HBV) can have mutations that include the a determinant, which causes breakthrough infection. In particular, a single mutation at amino acid 145 of the surface protein (G145) is frequently reported in the failure of prophylactic treatment. The aim of this study was to evaluate the frequency of the a determinant mutants, especially the G145 variant, in Japan, where universal vaccination has not been adopted.